Viveve Medical Inc (NASDAQ:VIVE) Stock Is Shorted More

June 14, 2018 - By Henry Gaston

The stock of Viveve Medical Inc (NASDAQ:VIVE) registered an increase of 5.89% in short interest. VIVE’s total short interest was 3.33M shares in June as published by FINRA. Its up 5.89% from 3.14M shares, reported previously. With 281,800 shares average volume, it will take short sellers 12 days to cover their VIVE’s short positions. The short interest to Viveve Medical Inc’s float is 37.34%.

The stock increased 7.04% or $0.19 during the last trading session, reaching $2.89. About 339,199 shares traded. Viveve Medical, Inc. (NASDAQ:VIVE) has declined 65.48% since June 14, 2017 and is downtrending. It has underperformed by 78.05% the S&P500.

Viveve Medical, Inc. designs, develops, makes, and markets medical devices for the non-invasive treatment of vaginal laxity. The company has market cap of $90.37 million. The firm offers Geneveve, a non-invasive solution that includes the Viveve System, a radio frequency generator; a reusable hand piece and single-use treatment tip; and other consumable accessories. It currently has negative earnings. It markets its products through sales employees and distributors in Asia, Europe, the Middle East, Latin America, the United States, Canada, and internationally.

More important recent Viveve Medical, Inc. (NASDAQ:VIVE) news were published by: which released: “Viveve Announces Settlement of Patent Infringement Litigation with Thermi” on June 04, 2018, also published article titled: “Viveve Announces Initiation of VIVEVE II Clinical Study”, published: “Mizuho Maintains Bullish View on Viveve Medical (VIVE) Following KOL Call” on June 14, 2018. More interesting news about Viveve Medical, Inc. (NASDAQ:VIVE) was released by: and their article: “Viveve to Present at Jefferies Global Healthcare Conference” with publication date: May 29, 2018.

Viveve Medical, Inc. (NASDAQ:VIVE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.